Case Report
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3357-3363
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3357
Figure 2
Figure 2 Response to combination therapy with encorafenib, binimetinib, and cetuximab. Computed tomography images before and after treatment with encorafenib, binimetinib, and cetuximab. The graph shows fluctuation of serum levels of carcinoembryonic antigen (CEA; normal range: 0-5 ng/mL), carbohydrate antigen 19-9 (CA 19-9; normal range: 0-37 U/mL) and lactate dehydrogenase (LDH; normal range: 124-222 U/L).

  • Citation: Sasaki M, Shimura T, Nishie H, Kuroyanagi K, Kanno T, Fukusada S, Sugimura N, Mizuno Y, Nukui T, Uno K, Kojima Y, Nishigaki R, Tanaka M, Ozeki K, Kubota E, Kataoka H. BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report. World J Gastrointest Oncol 2024; 16(7): 3357-3363
  • URL: https://www.wjgnet.com/1948-5204/full/v16/i7/3357.htm
  • DOI: https://dx.doi.org/10.4251/wjgo.v16.i7.3357